NCT00006228View on ClinicalTrials.gov

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

July 31, 2003

Conditions
HER2-positive Breast CancerMale Breast CancerRecurrent Breast CancerStage IV Breast Cancer
Interventions
BIOLOGICAL

trastuzumab

Given IV

BIOLOGICAL

aldesleukin

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006228 - Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter